topotecan has been researched along with Leukemia, Myelomonocytic, Chronic in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (85.71) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Diehl, V; Hoffmann, M; Seiberlich, B; Staib, P; Tesch, H; Weihrauch, MR | 1 |
| Abbruzzese, JL; al-Bitar, M; Andreeff, M; Arbuck, S; Beran, M; Estey, E; Kantarjian, H; Keating, M; Koller, C; Moore, M; O'Brien, S; Pierce, S | 1 |
| Beran, M; Kantarjian, H | 2 |
| Beran, M; Estey, E; Giles, FJ; Kantarjian, HM; Keating, M; Koller, CA; Kornblau, S; O'Brien, SM | 1 |
| Andreeff, M; Beran, M; Cortes, J; Estey, E; Giles, FJ; Hayes, K; Kantarjian, H; Keating, M; Koller, CA; Kornblau, S; O'Brien, S; Pierce, SR; Vey, N; Wong, GC | 1 |
5 trial(s) available for topotecan and Leukemia, Myelomonocytic, Chronic
| Article | Year |
|---|---|
Phase I/II clinical study of topotecan and cytarabine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia and acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Cytarabine; Disease-Free Survival; Female; Hemoglobinometry; Humans; Leukemia, Myeloid; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Survival Analysis; Topotecan; Treatment Outcome | 2004 |
Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Diarrhea; Female; Fever; Follow-Up Studies; Genes, ras; Humans; Leukemia, Myelomonocytic, Chronic; Life Tables; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Proteins; Remission Induction; Stomatitis; Survival Analysis; Survival Rate; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 1996 |
Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.
Topics: Adult; Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents; Chromosome Aberrations; Genes, ras; Humans; Infusions, Intravenous; Karyotyping; Leukemia, Myelomonocytic, Chronic; Middle Aged; Remission Induction; Survival Analysis; Topotecan; Treatment Outcome | 1998 |
Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Prognosis; Remission Induction; Topotecan | 1999 |
Results of topotecan-based combination therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Karyotyping; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Platelet Count; Remission Induction; Risk Assessment; Survival Rate; Thrombocytopenia; Topotecan | 1999 |
2 other study(ies) available for topotecan and Leukemia, Myelomonocytic, Chronic
| Article | Year |
|---|---|
Hycamtin achieves promising results in study of patients with leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Ovarian Neoplasms; Remission Induction; Topotecan | 1996 |
Topotecan in the treatment of hematologic malignancies.
Topics: Aged; Antineoplastic Agents; Enzyme Inhibitors; Humans; Leukemia, Myelomonocytic, Chronic; Middle Aged; Myelodysplastic Syndromes; Topotecan; Treatment Outcome | 1998 |